Table 1 Overview of patient and tumor characteristics
From: Breast cancer Intraoperative Margin Assessment using specimen PET-CT (BIMAP)
Category | Subcategory | Patients (n = 41) |
|---|---|---|
Age mean [min-max] (years) | 60 [38–81] | |
Length mean [min-max] (cm) | 164,1 [150–178] | |
Weight (mean [min-max]) (kg) | 70,8 (53-103) | |
Clinical stage (n (%)) | Tis | 2 (5%) |
T1a (≤5 mm) | 2 (5%) | |
T1b (≤10 mm) | 10 (24%) | |
T1c (≤20 mm) | 19 (46%) | |
T2 ( ≤ 50 mm) | 8 (20%) | |
N0 | 34 (83%) | |
N1a | 5 (12%) | |
N2a | 2 (5%) | |
Tumor Histology (n (%)) | IDC | 31 (75%) |
ILC | 6 (15%) | |
DCIS | 2 (5%) | |
NACT | 2 (5%) | |
Nothingham Grade (n (%)) | 1 | 9 (22%) |
2 | 20 (48%) | |
3 | 11 (27%) | |
N/A | 1 (3%) | |
Estrogen receptor (n (%)) | Negative | 3 (7%) |
Positive | 37 (90%) | |
N/A | 1 (3%) | |
Progesterone receptor (n (%)) | Negative | 9 (22%) |
Positive | 31 (75%) | |
N/A | 1 (3%) | |
HER2 amplification (n (%)) | Negative | 31 (75%) |
Positive | 6 (15%) | |
N/A | 4 (10%) | |
Ki-67 classification (n (%)) | High ( > 15%) | 17 (41%) |
Medium (10-15%) | 7 (17%) | |
low ( < 10%) | 15 (37%) | |
N/A | 2 (5%) |
